Search

Your search keyword '"Tigran G. Gevorkian"' showing total 15 results
Start Over Author "Tigran G. Gevorkian"
15 results on '"Tigran G. Gevorkian"'

1. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines

Author

Konstantin K. Laktionov, Elena V. Artamonova, Tatiana N. Borisova, Valeriy V. Breder, Iurii M. Bychkov, Liubov Iu. Vladimirova, Nikita M. Volkov, Stepan M. Ergnian, Albina S. Zhabina, Pavel V. Kononets, Alexander E. Kuzminov, Evgeny V. Levchenko, Olga A. Malikhova, Dimitr T. Marinov, Sergey V. Miller, Fedor V. Moiseenko, Valeriia V. Mochal’nikova, Sergei N. Novikov, Oleg V. Pikin, Elena V. Reutova, Evgenii O. Rodionov, Dina D. Sakaeva, Ksenia A. Sarantseva, Anna I. Semenova, Aleksei V. Smolin, Vladimir M. Sotnikov, Sergei A. Tuzikov, Igor N. Turkin, Igor E. Tyurin, Vladimir D. Chkhikvadze, Konstantin I. Kolbanov, Marina V. Chernykh, Andrei V. Chernichenko, Aleksandr A. Fedenko, Elena V. Filonenko, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, Tigran G. Gevorkian, Aleksei V. Butenko, Ilmira R. Gil’mutdinova, Irina V. Gridneva, Mikhail A. Eremushkin, Margarita A. Zernova, Boris S. Kasparov, Denis V. Kovlen, Kristina O. Kondrat’eva, Tatiana V. Konchugova, Svetlana B. Korotkova, Anton A. Krutov, Olga A. Obukhova, Gennadii N. Ponomarenko, Tatiana Iu. Semiglazova, Aleksandra M. Stepanova, and Marina M. Khulamkhanova

Subjects
lung cancer, bronchial cancer clinical guidelines, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2022
Full Text
View/download PDF

2. Gastric cancer: Russian clinical guidelines

Author

Nataliia S. Besova, Aleksei E. Kalinin, Sergei N. Nered, Aleksei A. Triakin, Sergei V. Gamaiunov, Nikolai A. Kozlov, Ivan S. Stilidi, Aleksei M. Karachun, Pavel V. Kononets, Olga A. Malikhova, Andrei B. Riabov, Vladimir M. Khomiakov, Aleksandr A. Fedenko, Larisa V. Bolotina, Natalia A. Falaleeva, Aleksei A. Nevol'skikh, Sergei A. Ivanov, Zhanna V. Khailova, Tigran G. Gevorkian, Aleksei V. Butenko, Ilmira R. Gil'mutdinova, Mikhail A. Eremushkin, Galina E. Ivanova, Kristina O. Kondrat'eva, Tatiana V. Konchugova, Anton A. Krutov, Olga A. Obukhova, Tatiana Iu. Semiglazova, Elena V. Filonenko, Marina M. Khulamkhanova, and Aleksandr I. Romanov

Subjects
gastric cancer, clinical guidelines, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Gastric cancer remains one of the most common malignancies in Russia. Despite steady decrease of gastric cancer incidence it still reaches 24.65 per 100 000 population (crude rate) in 2019 with about 36 000 new cases annually. More than 29 000 people die of gastric cancer every year. High mortality rate is mostly caused by an extremely significant proportion of patients with metastatic disease which reached 40.1% in 2019. The majority of cases is related to Helicobacter pylori infection, salty diet, tobacco exposure as well as hereditary syndromes. Staging of locally advanced gastric cancer includes contrast-enhanced computed tomography of the thorax, abdomen and pelvis as well as diagnostic laparoscopy with peritoneal washings. In patients with inoperable or disseminated cancer of the stomach additional analysis for HER2, microsatellite instability and PD-L1 status is recommended. Endoscopic or laparoscopic resection remains the mainstay of treatment in patients with early cancer. Laparoscopic gastrectomy in patients with locally advanced cancer is reserved for high-volume centers with extensive experience with the procedure. Recently, perioperative cytotoxic therapy became the standard of treatment in patients with locally advanced gastric cancer. FLOT regimen is recommended while FOLFOX6 or XELOX are considered possible in the elderly or frail patients. Drug therapy includes standard doublet or triplet chemotherapy regimens for metastatic disease with trastuzumab for HER2(+++) patients. Patients with MSI-H tumors can be treated with pembrolizumab starting with 2nd line while nivolumab is reserved for the 3rd and further lines regardless of PD-L1 status. Importantly, this year guidelines include multimodal prehabilitation including physical exercise, nutritional support and psychological counselling as a possibility in all patients in need of surgery. Also standardized enhanced recovery protocols are recommended for usage during the perioperative period.

Published
2021
Full Text
View/download PDF

3. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines

Author

Konstantin K. Laktionov, Elena V. Artamonova, Tatiana N. Borisova, Valerii V. Breder, Iurii M. Bychkov, Liubov Iu. Vladimirova, Nikita M. Volkov, Stepan M. Ergnian, Albina S. Zhabina, Pavel V. Kononets, Aleksandr E. Kuz’minov, Evgenii V. Levchenko, Olga A. Malikhova, Dimitr T. Marinov, Sergei V. Miller, Fedor V. Moiseenko, Valeriia V. Mochal’nikova, Sergei N. Novikov, Oleg V. Pikin, Elena V. Reutova, Evgenii O. Rodionov, Dina D. Sakaeva, Anna I. Semenova, Aleksei V. Smolin, Vladimir M. Sotnikov, Sergei A. Tuzikov, Igor N. Turkin, Igor E. Tiurin, Vladimir D. Chkhikvadze, Konstantin I. Kolbanov, Andrei V. Chernichenko, Aleksandr A. Fedenko, Elena V. Filonenko, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, Tigran G. Gevorkian, Aleksei V. Butenko, Ilmira R. Gil’mutdinova, Irina V. Gridneva, Mikhail A. Eremushkin, Margarita A. Zernova, Boris S. Kasparov, Denis V. Kovlen, Kristina O. Kondrat’eva, Tatiana V. Konchugova, Svetlana B. Korotkova, Anton A. Krutov, Olga A. Obukhova, Gennadii N. Ponomarenko, Tatiana Iu. Semiglazova, Aleksandra M. Stepanova, Galina A. Tkachenko, and Marina M. Khulamkhanova

Subjects
lung cancer, clinical guidelines, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Lung cancer has the highest morbidity rate among all malignant tumors in men and the highest mortality rate in men and women in Russia. In total, 49 145 new cases of lung cancer were registered (diagnosed) in Russia in 2019. The majority of cases are related to exogenic carcinogens and mainly tobacco smoke. For several decades surgical resection with preoperative cytotoxic therapy was an optimal approach for maximal cure rate. This year recommendations were updated with new strategies including adjuvant anti-PD-L1 atezolizumab following completion of chemotherapy in PD-L1 positive patients and osimertinib for EGFR mutated cases. For this moment available data suggest the increase in disease free survival. Strategic approach to treatment for inoperable patients varies according to the status of driver mutations. New approach includes pretreatment option of testing for a wide spectrum of alterations with NGS based panels. Significant changes were incorporated into treatment of ALK mutated NSCLC with two new options of brigatinib for TKI naive patients and lorlatinib for those who progress on second generation drugs. Treatment strategy for patients without activating mutations is based on PD-L1 status. Tsis year recommendations included atezolizumab as a new monotherapy option for patients with high depression of PD-L1. Also treatment options for pembrolizumab, nivolumab and atezolizimab were widened with prolonged treatment schedules.

Published
2021
Full Text
View/download PDF

4. Prostate cancer

Author

Andrei D. Kaprin, Boris Ia. Alekseev, Vsevolod B. Matveev, Dmitrii Iu. Pushkar’, Aleksandr V. Govorov, Nina A. Gorban’, Andrei A. Kirichek, Vitalii A. Biriukov, Mariia I. Volkova, Igor A. Gulidov, Iuliia V. Gumenetskaia, Valerii V. Krylov, Oleg B. Kariakin, Aleksei A. Krasheninnikov, Iurii S. Mardynskii, Kirill M. Niushko, Tatiana I. Zakharova, Andrei A. Kostin, Evgenii V. Khmelevskii, Aleksandr A. Fedenko, Larisa V. Bolotina, Natalia A. Falaleeva, Elena V. Filonenko, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, and Tigran G. Gevorkian

Subjects
prostatic cancer, clinical guidelines, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Prostate cancer (RPP) is a malignant neoplasm that arises from the epithelium of the prostate gland gland (PJ). Thethiology and pathogenesis of this disease remain poorly studied. Many studies are aimed at studying diet, food, hormonal impact, as well as infections in the etiology of the RLPG. The prevalence of RPL depends on ethnic and geographical features. The highest incidence of African Americans living in the United States (60% higher than that of white Americans), the least high - in the Chinese living in China [1]. In addition to racial features, the risk factors of the RPG are considering the genetic predisposition, the age of men and nutritional features. The probability of developing a PJ tumor in a man who has one of the closest relatives of the first degree of kinship (father or brother) sick of the RLPG, is 1.8 times higher than in the population. If two relatives were sick or more (father and brother or both brothers), the risk of RPG increases in 5.51 and 7.71 times, respectively [2, 3]. African Americans have an increased risk of identifying RPG, as well as a greater probability of detecting aggressive RPG [4]. Also, the risk of RLPG is rising in men who use a large amount of animal fats [5].

Published
2021
Full Text
View/download PDF

5. Breast cancer

Author

Liudmila G. Zhukova, Iuliia I. Andreeva, Larisa E. Zavalishina, Aziz D. Zakiriakhodzhaev, Irina A. Koroleva, Aleksei V. Nazarenko, Ruslan M. Paltuev, Anastasiia A. Parokonnaia, Aleksandr V. Petrovskii, Sergei M. Portnoi, Vladimir F. Semiglazov, Tatiana I. Semiglazova, Marina B. Stenina, Aleksandra M. Stepanova, Oxana P. Trofimova, Sergey A. Tyulyandin, Georgii A. Frank, Mona A. Frolova, Iuliana S. Shatova, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, and Tigran G. Gevorkian

Subjects
breast cancer, clinical guidelines, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Breast cancer (BC) is a malignant tumor originating from the epithelium of the breast tissue. There is no single etiological factor in the development of breast cancer. In 310% of patients with breast cancer, the development of the disease is associated with the presence of mutations in the breast cancer gene (BRCA) 1, BRCA2, CHEK, NBS1, TP53. In other patients, breast cancer is sporadic.

Published
2021
Full Text
View/download PDF

6. Multiple myeloma

Author

Larisa P. Mendeleeva, Olga M. Votiakova, Irina G. Rekhtina, Evgenii A. Osmanov, Irina V. Poddubnaya, Liudmila Iu. Grivtsova, Natalia A. Falaleeva, Vadim V. Baikov, Alla M. Kovrigina, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, and Tigran G. Gevorkian

Subjects
multiple myeloma, paraproteinemia, proteinuria, plasma cells, antitumor response, chemotherapy, high-dose chemotherapy, autologous hematopoietic stem cell transplantation, targeted therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Multiple myeloma

Published
2021
Full Text
View/download PDF

7. Differentiated thyroid cancer

Author

Dmitrii G. Bel’tsevich, Ali M. Mudunov, Vladimir E. Vanushko, Pavel O. Rumiantsev, Galina A. Mel’nichenko, Nikolai S. Kuznetsov, Sergei O. Podvyaznikov, Yuri V. Alymov, Andrei P. Poliakov, Valentin V. Fadeev, Mikhail V. Bolotin, Feliks E. Sevriukov, Valerii V. Krylov, Aleksandr A. Fedenko, Larisa V. Bolotina, Andrei A. Zharov, Natalia A. Falaleeva, Elena V. Filonenko, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, and Tigran G. Gevorkian

Subjects
differentiated thyroid cancer, clinical guidelines, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Differentiated thyroid cancer

Published
2021
Full Text
View/download PDF

8. Follicular lymphoma

Author

Lali G. Babicheva, G. S. Tumyan, E. A. Osmanov, N. A. Falaleeva, S. K. Kravchenko, D. N. Stefanov, I. V. Poddubnaya, N. V. Myakova, A. G. Rumyantsev, A. A. Maschan, V. V. Ptushkin, V. V. Baikov, Alla M. Kovrigina, Iurii A. Krivolapov, D. M. Konovalov, A. A. Nevolsky, S. A. Ivanov, Zh. V. Khaylova, and Tigran G. Gevorkian

Subjects
follicular lymphoma, clinical recommendations, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Clinical recommendations.

Published
2020
Full Text
View/download PDF

9. Solitary (extramedullary) plasmocytoma. Clinical recommendations

Author

Natal’ia A. Falaleeva, Alena Iu. Terekhova, Vadim V. Ptushkin, Evgenii A. Osmanov, Irina V. Poddubnaya, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, and Tigran G. Gevorkian

Subjects
plasmacytoma, clinical recommendations, marrow, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Solitary (extramedullary) plasmocytoma. Clinical recommendations

Published
2020
Full Text
View/download PDF

10. Hairy cell leukemia. Clinical recommendations

Author

Liubov S. Al’-Radi, Vadim V. Baikov, Alla M. Kovrigina, Iurii A. Krivolapov, Tatiana N. Moiseeva, Evgenii A. Nikitin, Aleksandr V. Pivnik, Elena A. Stadnik, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova, and Tigran G. Gevorkian

Subjects
hairy cell leukemia, splenomegaly, splenectomy, lymphocytosis, cladribine, interferon-alpha, glucocorticosteroid, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Hairy cell leukemia. Clinical recommendations

Published
2020
Full Text
View/download PDF

11. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines

Author

Andrei V. Chernichenko, Iurii M. Bychkov, Aleksandr A. Fedenko, Elena V. Artamonova, Tigran G. Gevorkian, Valeriia V. Mochal’nikova, Gennadii N. Ponomarenko, Zhanna V. Khailova, Sergei A. Ivanov, Svetlana B. Korotkova, Fedor Moiseenko, Irina V. Gridneva, Kristina O. Kondrat’eva, Aleksei V. Smolin, Anton A. Krutov, Tat'iana Iu Semiglazova, Dimitr T. Marinov, Mikhail A. Eremushkin, Sergei V. Miller, Vladimir D. Chkhikvadze, Evgenii O. Rodionov, T. N. Borisova, Sergei N. Novikov, Liubov' I Vladimirova, Denis V. Kovlen, Oleg V. Pikin, Konstantin Laktionov, Aleksei V. Butenko, Marina M. Khulamkhanova, A S Zhabina, Evgenii V. Levchenko, Valerii V. Breder, Igor N. Turkin, Nikita M. Volkov, Dina D. Sakaeva, Margarita A. Zernova, Elena V. Filonenko, Malikhova Oa, Olga A. Obukhova, Anna I. Semenova, Aleksandra M. Stepanova, Sergei A. Tuzikov, Tatiana V. Konchugova, Vladimir M. Sotnikov, Aleksandr E. Kuz’minov, Stepan M. Ergnian, Aleksei A. Nevol’skikh, Ilmira R. Gil’mutdinova, Galina A. Tkachenko, Igor E. Tiurin, Pavel V. Kononets, Boris Kasparov, Konstantin I. Kolbanov, and Elena V. Reutova

Subjects
lung cancer, Cancer Research, Pathology, medicine.medical_specialty, Lung, medicine.anatomical_structure, clinical guidelines, Oncology, business.industry, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Medicine, business, RC254-282
Abstract

Lung cancer has the highest morbidity rate among all malignant tumors in men and the highest mortality rate in men and women in Russia. In total, 49 145 new cases of lung cancer were registered (diagnosed) in Russia in 2019. The majority of cases are related to exogenic carcinogens and mainly tobacco smoke. For several decades surgical resection with preoperative cytotoxic therapy was an optimal approach for maximal cure rate. This year recommendations were updated with new strategies including adjuvant anti-PD-L1 atezolizumab following completion of chemotherapy in PD-L1 positive patients and osimertinib for EGFR mutated cases. For this moment available data suggest the increase in disease free survival. Strategic approach to treatment for inoperable patients varies according to the status of driver mutations. New approach includes pretreatment option of testing for a wide spectrum of alterations with NGS based panels. Significant changes were incorporated into treatment of ALK mutated NSCLC with two new options of brigatinib for TKI naive patients and lorlatinib for those who progress on second generation drugs. Treatment strategy for patients without activating mutations is based on PD-L1 status. Tsis year recommendations included atezolizumab as a new monotherapy option for patients with high depression of PD-L1. Also treatment options for pembrolizumab, nivolumab and atezolizimab were widened with prolonged treatment schedules.

Published
2021
Full Text
View/download PDF

12. Chronic lymphocytic leukemia/small lymphocytic lymphoma

Author

K. D. Kaplanov, N. A. Falaleeva, Olga Samoilova, T. N. Lopatkina, E. A. Osmanov, Zh. V. Khailova, Tigran G. Gevorkian, EA Stadnik, V. V. Baikov, I. V. Poddubnaya, E A Nikitin, L. Iseber, O. V. Mukhortova, Alla M. Kovrigina, T. E. Bialik, Sergei A. Ivanov, S. A. Lugovskaia, Aleksei A. Nevol’skikh, and A. Iu. Zaritskii

Subjects
1st line therapy, Cancer Research, business.industry, medicine.medical_treatment, Chronic lymphocytic leukemia, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, targeted therapy, medicine.disease, Lymphocytic lymphoma, Targeted therapy, immunochemotherapy, Oncology, immune system diseases, hemic and lymphatic diseases, Cancer research, medicine, chronic lymphocytic leukemia, business, small lymphocyte lymphoma, RC254-282, 2nd line therapy
Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma. Clinical recommendations

Published
2020
Full Text
View/download PDF

13. Mantle cell lymphoma

Author

G. S. Tumian, Tigran G. Gevorkian, Alla M. Kovrigina, N. A. Falaleeva, Zh. V. Khailova, Sergei A. Ivanov, V. I. Vorob’ev, Irina V. Poddubnaya, V. V. Baikov, E. A. Osmanov, Aleksei A. Nevol’skikh, and Vadim V. Ptushkin

Subjects
Cancer Research, Oncology, clinical guidelines, Chemistry, immune system diseases, hemic and lymphatic diseases, medicine, Cancer research, mantle cell lymphoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Mantle cell lymphoma, medicine.disease, RC254-282
Abstract

Mantle cell lymphoma. Clinical recommendations

Published
2020

14. Hairy cell leukemia. Clinical recommendations

Author

Evgenii A. Nikitin, Liubov S. Al’-Radi, Tigran G. Gevorkian, Zhanna V. Khailova, Tatiana N. Moiseeva, Vadim V. Baikov, Aleksei A. Nevol’skikh, Alla M. Kovrigina, Iurii A. Krivolapov, Pivnik Av, EA Stadnik, and Sergei A. Ivanov

Subjects
splenomegaly, Cancer Research, Lymphocytosis, interferon-alpha, business.industry, medicine.medical_treatment, Splenectomy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Alpha interferon, cladribine, lymphocytosis, medicine.disease, splenectomy, Oncology, hemic and lymphatic diseases, medicine, Cancer research, hairy cell leukemia, Hairy cell leukemia, medicine.symptom, glucocorticosteroid, Cladribine, business, RC254-282, medicine.drug
Abstract

Hairy cell leukemia. Clinical recommendations

Published
2020
Full Text
View/download PDF

15. Solitary (extramedullary) plasmocytoma. Clinical recommendations

Author

Aleksei A. Nevol’skikh, Vadim V. Ptushkin, N. A. Falaleeva, Tigran G. Gevorkian, Sergei A. Ivanov, Irina V. Poddubnaya, Evgenii A. Osmanov, Alena Iu. Terekhova, and Zhanna V. Khailova

Subjects
Cancer Research, medicine.medical_specialty, business.industry, marrow, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, clinical recommendations, Oncology, plasmacytoma, medicine, Plasmacytoma, Radiology, business, RC254-282
Abstract

Solitary (extramedullary) plasmocytoma. Clinical recommendations

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results